Sodium glucose transporter inhibition in heart failure From an unexpected side effect to a novel treatment possibility

Sodium-glucose transporter-2 inhibitors (SGLT2i), originally launched as glucose-lowering drugs, have been studied in large cardiovascular outcome trials to ascertain safety. Surprisingly, these compounds reduced the risk of cardiovascular events (cardiovascular death, non-fatal myocardial and non-fatal stroke) and total mortality. The mechanisms behind this benefit are only partly understood, but a major contributor is the reduction of heart failure hospitalisations, evident already within weeks after the initiation of the SGLT2i.

Source: Diabetes Research and Clinical Practice - April 9, 2021 Category: Endocrinology Authors: Giulia Ferrannini, Gianluigi Savarese, Lars Ryd én Source Type: research